FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W299894314> ?p ?o ?g. }

• W299894314 endingPage "6" @default.
• W299894314 startingPage "142" @default.
• W299894314 abstract "To observe the effect of Shenshuaining Granule (SG) combined telmisartan on serum creatinine (SCr) levels and urinary albumin contents in diabetic nephropathy (DN) patients, and to explore its efficacy.Totally 204 DN patients were recruited, and further assigned to 3 groups, i.e., the early DN group, the clinical stage of DN with normal renal function group, the clinical stage of DN with insufficient renal function group. Patients in the same group were randomly allocated to the telmisartan treatment group, the SG treatment group, and the combination of SG and telmisartan treatment group, 68 in each group. Patients in the telmisartan treatment group took telmisartan tablet, 80 mg per day, once daily. Those in the SG treatment group took SG, 5 g each time, 3 times per day. Those in the combination of SG and telmisartan treatment group took telmisartan tablet (80 mg per day, once daily) and SG (5 g each time, 3 times per day). The therapeutic course for all was 3 successive months. SCr levels, serum urea nitrogen (BUN),24 h urine microalbumin (24 h U-MA) were detected before and after treatment. Results In three different treatment groups, 24 h U-MA decreased after treatment in the telmisartan treatment group; SCr and BUN decreased after treatment in the SG treatment group; and 24 h U-MA, SCr and BUN decreased after treatment in the combination of SG and telmisartan treatment group (P<0.05). In the clinical stage of DN with insufficient renal function group, SCr obviously increased after treatment in the telmisartan treatment group (P <0. 05). In the 3 DN stages, SCr and 24 h U-MA obviously decreased in the combination of SG and telmisartan treatment group, when compared with the telmisartan treatment group and the SG treatment group (P<0.05). Compared with the telmisartan treatment group, SCr and BUN obviously decreased in the SG treatment group, but 24 h U-MA quantitation obviously increased (P<0.05). BUN obviously decreased in the combination of SG and telmisartan treatment group (P<0. 05).The combination of SG and telmisartan could decrease urinary albumin, and stabilize SCr levels." @default.
• W299894314 created "2016-06-24" @default.
• W299894314 creator A5012186250 @default.
• W299894314 creator A5017108478 @default.
• W299894314 creator A5028648076 @default.
• W299894314 creator A5038789183 @default.
• W299894314 creator A5075250772 @default.
• W299894314 date "2015-02-01" @default.
• W299894314 modified "2023-10-14" @default.
• W299894314 title "[Efficacy observation of treating diabetic nephropathy by shenshuaining granule combined telmisartan tablet]." @default.
• W299894314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25881456" @default.
• W299894314 hasPublicationYear "2015" @default.
• W299894314 type Work @default.
• W299894314 sameAs 299894314 @default.
• W299894314 citedByCount "2" @default.
• W299894314 countsByYear W2998943142022 @default.
• W299894314 countsByYear W2998943142023 @default.
• W299894314 crossrefType "journal-article" @default.
• W299894314 hasAuthorship W299894314A5012186250 @default.
• W299894314 hasAuthorship W299894314A5017108478 @default.
• W299894314 hasAuthorship W299894314A5028648076 @default.
• W299894314 hasAuthorship W299894314A5038789183 @default.
• W299894314 hasAuthorship W299894314A5075250772 @default.
• W299894314 hasConcept C126322002 @default.
• W299894314 hasConcept C126894567 @default.
• W299894314 hasConcept C159641895 @default.
• W299894314 hasConcept C2778176769 @default.
• W299894314 hasConcept C2779716603 @default.
• W299894314 hasConcept C2779922275 @default.
• W299894314 hasConcept C2780091579 @default.
• W299894314 hasConcept C2780306776 @default.
• W299894314 hasConcept C71924100 @default.
• W299894314 hasConcept C84393581 @default.
• W299894314 hasConcept C90924648 @default.
• W299894314 hasConceptScore W299894314C126322002 @default.
• W299894314 hasConceptScore W299894314C126894567 @default.
• W299894314 hasConceptScore W299894314C159641895 @default.
• W299894314 hasConceptScore W299894314C2778176769 @default.
• W299894314 hasConceptScore W299894314C2779716603 @default.
• W299894314 hasConceptScore W299894314C2779922275 @default.
• W299894314 hasConceptScore W299894314C2780091579 @default.
• W299894314 hasConceptScore W299894314C2780306776 @default.
• W299894314 hasConceptScore W299894314C71924100 @default.
• W299894314 hasConceptScore W299894314C84393581 @default.
• W299894314 hasConceptScore W299894314C90924648 @default.
• W299894314 hasIssue "2" @default.
• W299894314 hasLocation W2998943141 @default.
• W299894314 hasOpenAccess W299894314 @default.
• W299894314 hasPrimaryLocation W2998943141 @default.
• W299894314 hasRelatedWork W1522500493 @default.
• W299894314 hasRelatedWork W2007968870 @default.
• W299894314 hasRelatedWork W2348745344 @default.
• W299894314 hasRelatedWork W2349987816 @default.
• W299894314 hasRelatedWork W2355877427 @default.
• W299894314 hasRelatedWork W2363014881 @default.
• W299894314 hasRelatedWork W2392462062 @default.
• W299894314 hasRelatedWork W3032048370 @default.
• W299894314 hasRelatedWork W3201413063 @default.
• W299894314 hasRelatedWork W656697013 @default.
• W299894314 hasVolume "35" @default.
• W299894314 isParatext "false" @default.
• W299894314 isRetracted "false" @default.
• W299894314 magId "299894314" @default.
• W299894314 workType "article" @default.